Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
In this webinar, a detailed discussion is done on Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Speakers : Dr. Sushant Mittal - Moderator ,Dr. Randeep Singh - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Davinder Paul - Panelist
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
Early management of CNS metastases in ALK-positive NSCLC using next-gen ALK inhibitors improves intracranial control and patient outcomes.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
Explore innovative strategies for early CNS disease detection, integrating neuroimaging, biomarkers, and clinical assessment to enhance diagnostic precision and outcomes.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
Explore Lorlatinib’s role in first-line ALK+ mNSCLC treatment, highlighting key findings from the CROWN trial.`
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
In this webinar, a detailed discussion is done on Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
Explore treatment sequencing strategies for ALK+ NSCLC patients with CNS diseases, focusing on targeted therapies and CNS-penetrant treatments.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
Explore unmet needs in ALK-positive NSCLC, including resistance, CNS metastases, biomarker-driven therapies, and advances in precision oncology.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
Explore key findings from the CROWN trial for ALK+ NSCLC patients with CNS metastases and treatment advances.
Speakers : Dr. Sushant Mittal - Moderator ,Dr. Randeep Singh - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Davinder Paul - Panelist
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
2.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
3.
Kidney cancer: Understanding what a renal cell carcinoma diagnosis means
4.
AI tool automates liver tumor detection and monitoring
5.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
1.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
2.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
3.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
4.
How Cancer Cells Evade Immune Destruction and the Fight Back
5.
Unlocking The Causes And Risk Factors Of Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Current Scenario of Cancer- Q&A Session to Close the Gap
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge